Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997020 · ClinicalTrials.gov registry record
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)
A clinical trial of CRS, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT02997020: Active study of CRS, sponsored by University of Alabama at Birmingham.
NCT02997020 is a study of CRS that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997020, a study of CRS, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the novel endoscopically-directed sinus potential difference (EDSPD) assay as an endpoint for therapy of sinus disease.
Primary Outcome
To establish the relationship of EDSPD findings with other validated instruments and markers of CRS disease
Conditions Studied
Interventions
- OTHER EDSPD
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2026-04 |
What the registry record for NCT02997020 still lists
NCT02997020 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 1 condition, with CRS appearing as the primary indexed condition, and to 1 intervention - of which EDSPD is the first listed.
NCT02997020 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT02997020 about?
NCT02997020 is a clinical study titled "Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)". The purpose of this study is to establish the novel endoscopically-directed sinus potential difference (EDSPD) assay as an endpoint for therapy of sinus disease.
What is the current status of trial NCT02997020?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2017-05-18. Estimated completion is 2026-04.
What conditions does trial NCT02997020 study?
This clinical trial studies the following conditions: CRS.
What interventions are being tested in trial NCT02997020?
The interventions under investigation include: EDSPD (OTHER).
Who is sponsoring clinical trial NCT02997020?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997020 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI